Information Provided By: 
Fly News Breaks for February 22, 2018
PODD
Feb 22, 2018 | 04:55 EDT
Barclays analyst Matthew Taylor raised his price target for Insulet to $90 saying upside in both U.S. and international Omnipod revenue was a positive surprise in Q4. Install base growth remains strong and international growth has not been impacted by the pending transition to a direct selling model, Taylor tells investors in a post-earnings research note. The analyst sees "several catalysts" that should support growth over the next few years and continues to recommend Insulet with an Overweight rating.
News For PODD From the Last 2 Days
There are no results for your query PODD
